Welcome to our dedicated page for Hercules Capital news (Ticker: HTGC), a resource for investors and traders seeking the latest updates and insights on Hercules Capital stock.
Hercules Capital Inc. (NYSE: HTGC) maintains this dedicated news hub for investors tracking its specialty financing activities in technology, life sciences, and renewable energy sectors. Access timely updates on the company’s venture debt solutions, including senior secured loans and strategic partnerships with venture-backed enterprises.
This resource consolidates all official press releases and market-relevant developments, from quarterly earnings to executive leadership updates. Users will find detailed information on financing agreements, portfolio company milestones, and regulatory filings – essential for understanding HTGC’s role in venture growth capital markets.
Key content includes updates on biotechnology sector lending, renewable energy project financing, and structured debt arrangements with emerging technology firms. The curated news flow helps stakeholders monitor how Hercules Capital supports high-growth companies through customized financing solutions.
Bookmark this page for direct access to primary source materials about HTGC’s market activities. Check regularly for insights into how the company navigates opportunities in venture debt financing while maintaining its position as a leading provider of non-dilutive growth capital.
Hercules Capital (NYSE: HTGC) has received approval from the U.S. Small Business Administration (SBA) for its fourth Small Business Investment Company (SBIC) license. This approval grants Hercules access to an additional $175.0 million in long-term debentures, increasing its total borrowing capacity through the SBIC program to $350.0 million.
The SBIC program has been a important component of Hercules' funding strategy since 2006. This new license will enable the company to continue supporting innovative technology and life sciences companies seeking growth capital while maintaining a diversified balance sheet and favorable cost of capital. Hercules has also received exemptive relief from the SEC, allowing it to exclude SBIC leverage from applicable asset coverage limits.
NeueHealth has secured a term loan facility for up to $150 million with Hercules Capital, significantly strengthening its balance sheet. This financing aims to advance NeueHealth's differentiated care model and support the company's strategic priorities in 2024 and beyond. The loan will help NeueHealth deliver value-driven, consumer-centric care across the ACA Marketplace, Medicare, and Medicaid. Both companies expressed optimism about the partnership's potential to drive value for payors, providers, and consumers.
Harness has announced a $150 million financing round with investments from Silicon Valley Bank and Hercules Capital. This funding will support expanding the Harness platform, adding new modules, integrating generative AI, and investing in go-to-market strategies. The company, which has seen its Annual Recurring Revenue (ARR) grow from $1 million to over $100 million in five years, aims to enhance developer productivity and reduce non-code-producing work.
Key milestones include 44 million code deployments in 2023, the introduction of generative AI assistant AIDATM, launch of four new product modules, and the addition of enterprise customers like Nike and NetApp. The financing will enable Harness to continue innovating and expanding its market-leading software delivery platform.
Hercules Capital, Inc. (NYSE: HTGC) has announced that its 2024 Annual Meeting of Stockholders will be held virtually on June 20, 2024. The meeting will cover important matters such as the election of directors, executive compensation, authorization to sell shares below NAV, and ratification of the accounting firm.
Electric Hydrogen secured a $100M credit facility from HSBC, J.P. Morgan, Stifel Bank, and Hercules Capital to support the manufacturing and deployment of their 100MW electrolyzer plants for the production of green hydrogen. The funding will enable Electric Hydrogen to advance its mission of decarbonizing critical industries such as steel, fertilizer, shipping, and aviation.
Hercules Capital, Inc. (NYSE: HTGC) announced their participation in the Wells Fargo 2024 Financial Services Investor Conference. The event will provide an opportunity for the financial community to engage with the company's executive management team.
Hercules Capital, Inc. (NYSE: HTGC) reported record Q1 2024 financial results with total gross debt and equity commitments up by 81.7%, gross fundings up by 27.1%, total investment income up by 15.7%, net investment income up by 20.9%, NII providing 125% coverage of base cash distribution, undistributed earnings spillover of $142.7 million, approximately $4.5 billion of assets under management, and conservative balance sheet management.
Hercules Capital, Inc. (NYSE: HTGC) declared a total cash distribution of $0.48 per share for the first quarter of 2024, consisting of a $0.40 per share base distribution and an $0.08 per share supplemental distribution. The company aims to distribute 90% to 100% of its taxable quarterly income or potential annual income. The distributions declared in the first quarter of 2024 were derived from the company's current and accumulated earnings and profits. Hercules also designated 83.85% of Qualified Interest Income for the first quarter of 2024 as exempt from U.S. withholding tax for non-U.S. shareholders.
SynOx Therapeutics has secured a $35m debt financing with Hercules Capital to advance the development and commercialization of emactuzumab, a potential best-in-class CSF1(R) inhibiting monoclonal antibody. The company is conducting a Phase 3 study for the treatment of Tenosynovial Giant Cell Tumour (TGCT) and other diseases. The loan facility will support clinical work, registration, and commercialization of emactuzumab, enhancing the company's financial position.
FAQ
What is the current stock price of Hercules Capital (HTGC)?
What is the market cap of Hercules Capital (HTGC)?
